Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES

NCT05160922 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT05160922
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05160922 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Active, not recruiting
Start date
December 27, 2021
Completion date
March 21, 2028
Enrollment
27 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

alcl, imt, nsclc